NRX Pharmaceuticals, Inc. Fair Value Adjustment of Warrants
NRX Pharmaceuticals, Inc. (NRXP) reported Fair Value Adjustment of Warrants of $9.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was $9.78M, a 52.54% increase year-over-year.
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$3.54M.
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$3.56M, a 294.16% decline year-over-year.
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was $4.96M.
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2025 was $4.93M, a 197.28% increase from fiscal 2024.
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2024 was $1.66M.
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2023 was -$20.00K.
- NRX Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2022 was -$255.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.78M 10-Q · filed 2026-08-14 | $6.25M 10-Q · filed 2026-08-14 | $2.69M derived: sum of 3 quarters · filed 2026-08-14 | $7.65M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | -$3.54M 10-Q · filed 2026-05-15 | -$7.09M derived: sum of 2 quarters · filed 2026-05-15 | -$2.13M derived: sum of 3 quarters · filed 2026-05-15 | $4.28M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | -$3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.41M derived: sum of 2 quarters · filed 2026-03-23 | $7.82M derived: sum of 3 quarters · filed 2026-08-14 | $4.93M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $4.96M 10-Q · filed 2025-11-14 | $11.38M derived: sum of 2 quarters · filed 2026-08-14 | $8.48M 10-Q · filed 2025-11-14 | $10.31M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $6.41M 10-Q · filed 2026-08-14 | $3.52M 10-Q · filed 2026-08-14 | $5.35M derived: sum of 3 quarters · filed 2026-08-14 | $5.18M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | -$2.90M 10-Q · filed 2026-05-15 | -$1.06M derived: sum of 2 quarters · filed 2026-05-15 | -$1.23M derived: sum of 3 quarters · filed 2026-05-15 | -$1.25M derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.67M derived: sum of 2 quarters · filed 2026-03-23 | $1.65M derived: sum of 3 quarters · filed 2026-03-23 | $1.66M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | -$165.00K 10-Q · filed 2025-11-14 | -$183.00K derived: sum of 2 quarters · filed 2025-11-14 | -$174.00K 10-Q · filed 2025-11-14 | -$167.00K derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | -$18.00K 10-Q · filed 2025-08-18 | -$9.00K 10-Q · filed 2025-08-18 | -$2.00K derived: sum of 3 quarters · filed 2025-08-18 | -$28.00K derived: sum of 4 quarters · filed 2025-08-18 | |||
| 2024-03-31 | $9.00K 10-Q · filed 2025-05-15 | $16.00K derived: sum of 2 quarters · filed 2025-05-15 | -$10.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.00K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$19.00K derived: sum of 2 quarters · filed 2025-03-14 | -$8.00K derived: sum of 3 quarters · filed 2025-03-14 | -$20.00K 10-K · filed 2025-03-14 | |||
| 2023-09-30 | -$26.00K 10-Q · filed 2024-11-14 | -$15.00K derived: sum of 2 quarters · filed 2024-11-14 | -$27.00K 10-Q · filed 2024-11-14 | -$2.93M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-06-30 | $11.00K 10-Q · filed 2024-08-14 | -$1.00K 10-Q · filed 2024-08-14 | -$2.90M derived: sum of 3 quarters · filed 2025-05-15 | -$2.87M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-03-31 | -$2.90M 10-Q · filed 2025-05-15 | -$12.00K 10-Q · filed 2023-05-15 | -$2.92M derived: sum of 2 quarters · filed 2025-05-15 | -$2.88M derived: sum of 3 quarters · filed 2025-05-15 | -$2.99M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2022-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $18.00K derived: sum of 2 quarters · filed 2024-03-29 | -$98.00K derived: sum of 3 quarters · filed 2024-03-29 | -$255.00K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$79.00K derived: sum of 2 quarters · filed 2023-11-14 | -$236.00K 10-Q · filed 2023-11-14 | -$1.10M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | -$116.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$273.00K 10-Q · filed 2023-08-14 | -$1.14M derived: sum of 3 quarters · filed 2023-08-14 | $15.39M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$157.00K 10-Q · filed 2023-05-15 | -$1.03M derived: sum of 2 quarters · filed 2023-05-15 | $15.51M derived: sum of 3 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$869.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $15.67M derived: sum of 2 quarters · filed 2023-03-31 | -$1.69M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $16.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$823.00K 10-Q · filed 2022-11-14 | -$1.21M 10-Q · filed 2021-11-15 | ||||
| 2021-06-30 | -$17.36M 10-Q · filed 2022-08-15 | -$1.47M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |